Monopar Therapeutics Statistics
Share Statistics
Monopar Therapeutics has 5.28M shares outstanding. The number of shares has increased by -76.32% in one year.
| Shares Outstanding | 5.28M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | -79.87% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 3.13M |
| Failed to Deliver (FTD) Shares | 21.40K |
| FTD / Avg. Volume | 3.46% |
Short Selling Information
The latest short interest is 49.85K, so 0.94% of the outstanding shares have been sold short.
| Short Interest | 49.85K |
| Short % of Shares Out | 0.94% |
| Short % of Float | 1.59% |
| Short Ratio (days to cover) | 0.15 |
Valuation Ratios
The PE ratio is -2.94 and the forward PE ratio is -7.31.
| PE Ratio | -2.94 |
| Forward PE | -7.31 |
| PS Ratio | 0 |
| Forward PS | null |
| PB Ratio | 4.41 |
| P/FCF Ratio | -3.14 |
| PEG Ratio | n/a |
Enterprise Valuation
Monopar Therapeutics Inc. has an Enterprise Value (EV) of -.
| EV / Earnings | null |
| EV / Sales | null |
| EV / EBITDA | null |
| EV / EBIT | null |
| EV / FCF | null |
Financial Position
The company has a current ratio of 4.17, with a Debt / Equity ratio of 0.
| Current Ratio | 4.17 |
| Quick Ratio | 4.17 |
| Debt / Equity | 0 |
| Total Debt / Capitalization | 0 |
| Cash Flow / Debt | 0 |
| Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is -1.5% and return on capital (ROIC) is -158.05%.
| Return on Equity (ROE) | -1.5% |
| Return on Assets (ROA) | -1.14% |
| Return on Capital (ROIC) | -158.05% |
| Revenue Per Employee | 0 |
| Profits Per Employee | -933.58K |
| Employee Count | 9 |
| Asset Turnover | 0 |
| Inventory Turnover | 0 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by 1277.17% in the last 52 weeks. The beta is 1.1, so Monopar Therapeutics 's price volatility has been higher than the market average.
| Beta | 1.1 |
| 52-Week Price Change | 1277.17% |
| 50-Day Moving Average | 15.61 |
| 200-Day Moving Average | 6.55 |
| Relative Strength Index (RSI) | 67.67 |
| Average Volume (20 Days) | 618.97K |
Income Statement
In the last 12 months, Monopar Therapeutics had revenue of $0 and earned -$8.40M in profits. Earnings per share was $-0.58.
| Revenue | 0 |
| Gross Profit | 0 |
| Operating Income | -8.83M |
| Net Income | -8.40M |
| EBITDA | 429.04K |
| EBIT | - |
| Earnings Per Share (EPS) | -0.58 |
Balance Sheet
The company has $7.27M in cash and $0 in debt, giving a net cash position of $7.27M.
| Cash & Cash Equivalents | 7.27M |
| Total Debt | 0 |
| Net Cash | 7.27M |
| Retained Earnings | -60.21M |
| Total Assets | 6.07M |
| Working Capital | 6.07B |
Cash Flow
In the last 12 months, operating cash flow was -$7.86M and capital expenditures $0, giving a free cash flow of -$7.86M.
| Operating Cash Flow | -7.86M |
| Capital Expenditures | 0 |
| Free Cash Flow | -7.86M |
| FCF Per Share | -0.54 |
Margins
Gross margin is 0%, with operating and profit margins of 0% and 0%.
| Gross Margin | 0% |
| Operating Margin | 0% |
| Pretax Margin | 0% |
| Profit Margin | 0% |
| EBITDA Margin | n/a% |
| EBIT Margin | n/a% |
| FCF Margin | n/a% |
Dividends & Yields
MNPR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -2.29% |
| FCF Yield | -5.88% |
Analyst Forecast
The average price target for MNPR is $22, which is -13.2% lower than the current price. The consensus rating is "Buy".
| Price Target | $22 |
| Price Target Difference | -13.2% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
Stock Splits
The last stock split was on Aug 13, 2024. It was a backward split with a ratio of 1:5.
| Last Split Date | Aug 13, 2024 |
| Split Type | backward |
| Split Ratio | 1:5 |
Scores
| Altman Z-Score | 1249.4 |
| Piotroski F-Score | 1 |